Literature DB >> 20798235

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Shaji Kumar1, Angela Dispenzieri, Jerry A Katzmann, Dirk R Larson, Colin L Colby, Martha Q Lacy, Suzanne R Hayman, Francis K Buadi, Nelson Leung, Steve R Zeldenrust, Marina Ramirez-Alvarado, Raynell J Clark, Robert A Kyle, S Vincent Rajkumar, Morie A Gertz.   

Abstract

Immunoglobulin free light chains (FLCs) are the precursors of amyloid fibrils in primary amyloidosis (AL). We studied the relationship between FLC levels and clinical features in 730 patients with newly diagnosed AL. The plasma cell clone was λ in 72% patients, and κ in 28% patients. κ-AL had more GI tract and liver involvement, where as renal involvement was more with λ-AL. While the overall survival (OS) was similar for κ and λ-AL, the median OS for those without an identifiable serum heavy chain was significantly shorter (12.6 vs 29.9 months; P = .02). The OS was shorter among those with a higher dFLC (involved FLC-uninvolved FLC; κ > 29.4 mg/dL or λ > 18.2 mg/dL using median for cutoff); 10.9 vs 37.1 months; P < .001. In multivariate analysis, dFLC was independent of other prognostic factors. The type of light chain impacts the spectrum of organ involvement and the FLC burden correlates with survival in AL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20798235      PMCID: PMC3012533          DOI: 10.1182/blood-2010-06-290668

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Authors:  A R Bradwell; H D Carr-Smith; G P Mead; L X Tang; P J Showell; M T Drayson; R Drew
Journal:  Clin Chem       Date:  2001-04       Impact factor: 8.327

2.  "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases.

Authors:  R A KYLE; E D BAYRD
Journal:  Arch Intern Med       Date:  1961-03

3.  Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; Raynell J Clark; Arthur R Bradwell; L Joseph Melton; Dirk R Larson; Matthew F Plevak; Jerry A Katzmann
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

4.  Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Authors:  V Sanchorawala; D C Seldin; B Magnani; M Skinner; D G Wright
Journal:  Bone Marrow Transplant       Date:  2005-10       Impact factor: 5.483

5.  Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.

Authors:  Harun Akar; David C Seldin; Barbarajean Magnani; Carl O'Hara; John L Berk; Christopher Schoonmaker; Howard Cabral; Laura M Dember; Vaishali Sanchorawala; Lawreen H Connors; Rodney H Falk; Martha Skinner
Journal:  Amyloid       Date:  2005-12       Impact factor: 7.141

6.  Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.

Authors:  Jerry A Katzmann; Roshini S Abraham; Angela Dispenzieri; John A Lust; Robert A Kyle
Journal:  Clin Chem       Date:  2005-03-17       Impact factor: 8.327

7.  Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Authors:  R A Kyle; M A Gertz
Journal:  Semin Hematol       Date:  1995-01       Impact factor: 3.851

Review 8.  Amyloidosis: clinical, pathologic, and biochemical characteristics.

Authors:  M Skinner; A S Cohen
Journal:  Monogr Pathol       Date:  1983

9.  Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.

Authors:  Roshini S Abraham; Jerry A Katzmann; Raynell J Clark; A R Bradwell; Robert A Kyle; Morie A Gertz
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

10.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

View more
  33 in total

1.  High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.

Authors:  Sumit Madan; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; David Dingli; S Vincent Rajkumar; William J Hogan; Nelson Leung; Martha Grogan; Morie A Gertz
Journal:  Blood       Date:  2011-12-06       Impact factor: 22.113

2.  In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.

Authors:  Elena S Klimtchuk; Tatiana B Prokaeva; Brian H Spencer; Olga Gursky; Lawreen H Connors
Journal:  Amyloid       Date:  2017-06-20       Impact factor: 7.141

Review 3.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

4.  Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.

Authors:  Patrizia Tosi; Simona Tomassetti; Anna Merli; Valentina Polli
Journal:  Ther Adv Hematol       Date:  2013-02

5.  Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Authors:  Donna E Reece; Ute Hegenbart; Vaishali Sanchorawala; Giampaolo Merlini; Giovanni Palladini; Joan Bladé; Jean-Paul Fermand; Hani Hassoun; Leonard Heffner; Vishal Kukreti; Robert A Vescio; Lixia Pei; Christopher Enny; Dixie-Lee Esseltine; Helgi van de Velde; Andrew Cakana; Raymond L Comenzo
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

6.  Factoring in the missing link.

Authors:  Nilay Sethi; Reza Sedighi Manesh; Adam Sperling; Scott C Bresler; Nathan T Connell; Lawrence M Tierney
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

7.  Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Authors:  Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Brian K Link; Cristine Allmer; Clive S Zent; Timothy G Call; Kari G Rabe; Curtis A Hanson; Neil E Kay; Susan L Slager; Thomas E Witzig; Tait D Shanafelt
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

8.  Acute liver failure due to primary amyloidosis in a nephrotic syndrome: a swiftly progressive course.

Authors:  Brigite Aguiar Cardoso; Rita Leal; Helena Sá; Mário Campos
Journal:  BMJ Case Rep       Date:  2016-03-10

9.  A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Authors:  Vaishali Sanchorawala; Giovanni Palladini; Vishal Kukreti; Jeffrey A Zonder; Adam D Cohen; David C Seldin; Angela Dispenzieri; Arnaud Jaccard; Stefan O Schönland; Deborah Berg; Huyuan Yang; Neeraj Gupta; Ai-Min Hui; Raymond L Comenzo; Giampaolo Merlini
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

10.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.